The Global Asthma Network (GAN), established in 2012, followed the International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700 000 adolescents and children from 156 centres in 56 countries; it found marked worldwide variation in symptom prevalence of asthma, rhinitis and eczema that was not explained by the current understanding of these diseases; ISAAC Phase Three involved over 1 187 496 adolescents and children (237 centres in 98 countries). It found that asthma symptom prevalence was increasing in many locations especially in low- and middle-income countries where severity was also high, and identified several environmental factors that required further investigation.GAN Phase I, described in this article, builds on the ISAAC findings by collecting further information on asthma, rhinitis and eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital admissions, management and use of asthma essential medicines. The subjects will be the same age groups as ISAAC, and their parents. In this first global monitoring of asthma in children and adults since 2003, further evidence will be obtained to understand asthma, management practices and risk factors, leading to further recognition that asthma is an important non-communicable disease and to reduce its global burden.
agement of patients with chronic airfl ow limitation in resource-limited settings should also be clarifi ed. Unfortunately, quality-assured essential medicine, such as inhaled corticosteroids and bronchodilators, for patients with airfl ow limitation may not be accessible or affordable in low-and middle-income countries. 5 Even simple diagnostic tools such as peak fl ow meters are usually not available, let alone spirometers, and large numbers of patients in resource-limited settings repeatedly make unplanned health visits due to asthma attacks or exacerbations of chronic obstructive pulmonary disease in the absence of long-term management and care. Intention to treat therefore demands a system-wide approach to address the needs of the vulnerable. The second WSD, on 27 June 2012, will be an opportunity to raise awareness about lung health, although its objectives need to be clarifi ed. While spirometry is recommended for the diagnosis of airfl ow limitation in patients with respiratory symptoms, several professional societies recommend against using it in individuals without respiratory symptoms, as it involves substantial cost and may result in over-diagnosis due to false-positive results, unnecessary disease labelling, and inadequate use of medicine without clear benefi t in reducing future risks of exacerbation and lung function decline. 4 Further, providing individuals with their spirometry results was not found to independently improve smoking cessation or the likelihood of continued abstinence. 4 WSD should therefore aim at raising awareness about lung health, but not at using spirometry screening among asymptomatic individuals. As screening without adequate follow-up care will yield no benefi t, intention to test should be intention to treat.The contribution of WSD in improving the man- Published by The Union (www.theunion.org), PHA provides a platform to fulfi l its mission, 'Health solutions for the poor'. PHA publishes high-quality scientifi c research that provides new knowledge to improve the accessibility, equity, quality and effi ciency of health systems and services.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.